Advances in Glycoconjugate Vaccines and Nanovaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 December 2024 | Viewed by 172
Special Issue Editors
Interests: syndetic organic chemistry; medicinal chemistry; chemical biology; protein engineering; biocatalysis
Special Issues, Collections and Topics in MDPI journals
Interests: rational design and analytical characterization by MS-based approaches of naturally and synthetically glycosylated proteins (e.g., glycoconjugate vaccines, monoclonal antibodies) and nanoparticles
Special Issue Information
Dear Colleagues,
Glycoconjugate vaccines, obtained by linking carbohydrates to protein carriers, have had a critical role in fighting infectious diseases. RNA-based technologies are a novel approach to developing anti-infection and anti-cancer vaccines from preclinical to clinical stages. They are particularly effective in targeting carbohydrates, one of the most important classes of surface antigens, and can also be used as adjuvants to promote immunostimulant effects.
While traditional conjugation approaches and using soluble proteins as carriers have been common, recent advancements have been made in the field. New glycosylation strategies have been established, and nanotechnology is increasingly used in vaccine development. Chemically glycosylated organic and inorganic nanoparticles are being used to enhance immunostimulation and delivery. Finally, the complexity of glycoconjugate structures requires suitable analytical methods to support their design and development.
We are pleased to invite you to contribute to this Special Issue, which will focus on recent advancements in the design, development, and characterization of glycosylated proteins and nanoparticles as potential vaccines. The Special Issue is open to original research articles and reviews on antigenic/immunogenic oligosaccharides or new glyco-derivatives, as well as pre-clinical and clinical studies on anti-infection or anticancer glyco-(nano)vaccines. Investigations on analytical approaches to support the design and production of glycoconjugates will also be considered.
We look forward to receiving your contributions.
Prof. Dr. Marco Terreni
Dr. Sara Tengattini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glycoconjugate vaccines
- infection diseases
- anticancer vaccines
- glycosylated nanovaccines
- antigenic saccharides
- conjugation chemistry
- glycoconjugate characterization
- dual-acting vaccines
- glycosylated nanoparticles
